Paquinimod-d5-1

Paquinimod-d5-1 is a deuterated analog of Paquinimod (HY-100442) . Paquinimod (ABR 215757) is a specific and orally active inhibitor of S100A8/S100A9. Paquinimod rescues the pneumonia with substantial reduction of viral loads in SARS-CoV-2-infected mice[1][2][3].

Product Specifications

Product Name Alternative

ABR-215757-d5-1; ABR 25757-d5-1

UNSPSC

12352005

Target

Isotope-Labeled Compounds; SARS-CoV

Type

Isotope-Labeled Compounds

Related Pathways

Anti-infection; Others

Applications

Metabolism-protein/nucleotide metabolism

Field of Research

Metabolic Disease; Inflammation/Immunology

Purity

98.19

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

O=C(N(C1=C([2H])C([2H])=C([2H])C([2H])=C1[2H])CC)C2=C(C3=C(N(C2=O)C)C=CC=C3CC)O

Molecular Formula

C21H17D5N2O3

Molecular Weight

355.44

References & Citations

[1]Schelbergen RF, et al. Prophylactic treatment with S100A9 inhibitor paquinimod reduces pathology in experimental collagenase-induced osteoarthritis. Ann Rheum Dis. 2015 Dec;74 (12) :2254-8.|[2]Schelbergen RF, et al. Prophylactic treatment with S100A9 inhibitor paquinimod reduces pathology in experimental collagenase-induced osteoarthritis. Ann Rheum Dis. 2015 Dec;74 (12) :2254-8.|[3]Qirui Guo, et al. Induction of alarmin S100A8/A9 mediates activation of aberrant neutrophils in the pathogenesis of COVID-19. Cell Host Microbe. 2021 Feb 10;29 (2) :222-235.e4.|[4]Tahvili S, et al. Paquinimod prevents development of diabetes in the non-obese diabetic (NOD) mouse. PLoS One. 2018 May 9;13 (5) :e0196598.|[5]Tahvili S, et al. Paquinimod prevents development of diabetes in the non-obese diabetic (NOD) mouse. PLoS One. 2018 May 9;13 (5) :e0196598.